Lincoln Pharmaceuticals (NSE:LINCOLN, BOM:531633) has begun the trial run of a new manufacturing facility at Gandhinagar in Gujarat, India, according to a Wednesday filing to the Indian stock exchanges.
The new facility is expected to begin commercial production of active pharmaceutical ingredients in one to two years, subject to additional product permission received from the Food and Drugs Control Administration.
The facility has been set up with an investment of 40 million Indian rupees and will lead to a proposed capacity addition of 1.2 tons per annum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.